The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in people with HIV is relatively common. Dr Richard Sterling (Virginia Commonwealth University, Richmond, VA, USA) joins touchINFECTIOUS DISEASES to discuss the pathogenesis and factors associated with the development of fatty liver in people with HIV, biomarkers proven effective for NAFLD in HIV, and the research priorities in HIV-associated NAFLD.
The presentation entitled: ‘Diagnosis and Epidemiology of NAFLD/NASH in HIV–Unique Opportunities and Challenges’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.
Questions:
- Could you give us a brief overview of the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in people with HIV?
- What is known about the pathogenesis of NAFLD in HIV?
- What factors are associated with the development of fatty liver in people with HIV?
- What biomarkers have proven effective for NAFLD in HIV?
- What are the research priorities in HIV-associated NAFLD and what studies are ongoing?
Disclosures: Richard Sterling receives or has received grant/research Support from Abbie, Abbott, Gilead, and Roche.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
